alarm Free 2 Day Shipping over $49
Questions? 1 (844) 844 0031
click subdirectory_arrow_left
10
%
OFF
On Your
First Order
25
%
OFF
On Your
First Order
25
%
OFF
On Your
First Order
10
$
OFF
On Your
First Order
Click to open
expanded view

Orbax Oral Suspension

For the treatment of urinary tract, skin & soft tissue infections

Species: Dog Cat
Prescription required
Strength:
FREE shipping over $49
Ships Free!

Orbax Oral Suspension

For the treatment of urinary tract, skin & soft tissue infections

Species: Dog Cat
Prescription required
Strength:
FREE shipping over $49
Ships Free!
Product images:

Product description

Orbax Oral Suspension is for oral use in cats and dogs only.

Active ingredients

Each mL of Orbax Oral Suspension contains:

  • Orbifloxacin 30 mg

Indications for use

Orbax Oral Suspension is indicated for the treatment of:

  • urinary tract infections (cystitis) caused by susceptible strains of Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli and Enterococcus faecalis.

  • skin and soft tissue infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, coagulase positive staphylococci, Pasteurella multocida, Proteus mirabilis, Pseudomonas spp., Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Citrobacter spp., Enterococcus faecalis, β-hemolytic streptococci (Group G) and Streptococcus equisimilis.

Administration and dosage

  • Before initial use:

    • Remove the cap and insert the syringe adaptor by pressing firmly into top of bottle.
    • Insert the syringe tip into the adaptor opening and invert the bottle.
    • Withdraw the required amount of medication with the calibrated syringe.
    • After use, replace cap, leaving adaptor in the bottle, and rinse the syringe with water.
  • The dose of Orbax Oral Suspension is 1.1 to 3.4 mg/lb (2.5 to 7.5 mg/kg) of body weight administered once daily (See Drug interactions and Animal Safety).

  • The determination of dosage for any particular patient must take into consideration such factors as the severity and nature of the infection, the susceptibility of the causative organism, and the integrity of the patient’s host-defense mechanisms.

  • Antibiotic susceptibility of the pathogenic organism(s) should be determined prior to use of this preparation. Therapy with Orbax Oral Suspension may be initiated before results of these tests are known. Once results become available, continue with appropriate therapy.

  • For the treatment of skin infections, Orbax Oral Suspension should be given for two to three days beyond the cessation of clinical signs to a maximum of 30 days.

  • For the treatment of urinary tract infections, Orbax Oral Suspension should be administered for at least 10 consecutive days. If no improvement is seen within five days, the diagnosis should be re-evaluated and a different course of therapy considered.